Entities / Company
FibroGen (United States).
company in San Francisco, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 20
What's happening
Gone quiet
No new reports in 90+ days-
FibroGen received positive feedback from the FDA on a Type C meeting and increased the transaction consideration for the sale of FibroGen China.Some support1 report1 development inside
-
Positive Type C meeting supports advancement of roxadustat.Some support2 reports
-
FibroGen, a biotech drug developer, underperformed the market so far this year as of August 12, 2025.Some support1 report
-
AstraZeneca is acquiring FibroGen China assets, which was approved by the China State Administration for Market Regulation.Some support2 reports
-
H.C. Wainwright facilitated investor meetings for FibroGen on August 28, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around FibroGen (United States) this week
News at the entities that move FibroGen (United States) most-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves FibroGen (United States)
-
AstraZeneca TransactionalAstraZeneca is relocating its registered office from Karnataka to Bengaluru, citing proximity to policy and financial ecosystems.Moves FibroGen (United States)
-
Europe Shared contextBoth Africa and Europe are facing severe threats from habitat loss and wildlife population decline.Moves FibroGen (United States)
Connections
The 3 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AstraZeneca Transactional
AstraZeneca acquired FibroGen China and its assets through a series of sales and acquisitions.
-
FDA Structural
FibroGen's drug development and advancement are formally regulated by the FDA, which provides guidance and clearance.
-
Europe Shared context
FibroGen's product, Roxadustat, has received regulatory approval within the European market.
History
Events by the month they beganJune 2026
5 events- FibroGen received positive feedback from the FDA on a Type C meeting and increased the transaction consideration for the sale of FibroGen China.
- Positive Type C meeting supports advancement of roxadustat.
- FibroGen, a biotech drug developer, underperformed the market so far this year as of August 12, 2025.
- AstraZeneca is acquiring FibroGen China assets, which was approved by the China State Administration for Market Regulation.
- H.C. Wainwright facilitated investor meetings for FibroGen on August 28, 2025.